| PMC full text: | J Nucl Med. Author manuscript; available in PMC 2014 Apr 10. Published in final edited form as: J Nucl Med. 2012 Oct; 53(10): 1592–1600. Published online 2012 Aug 23. doi: 10.2967/jnumed.111.102293 |
TABLE 1
Comparison of tumor to muscle ratios of 89Zr-df-Onartuzumab and 76Br-Onartuzumab in MKN-45 xenografts from 6 h to 120 h.
| Tumor to muscle ratios* | |||||||
|---|---|---|---|---|---|---|---|
| Time of Uptake (h) | 6 | 18 | 24 | 48 | 72 | 96 | 120 |
| 89Zr-df-Onartuzumab | -- | 6.4 (0.4) | 7.1 (1.0) | 13.2 (2.4) | 12.2 (2.3) | 19.6 (2.4) | 26.6 (0.9) |
| 76Br-Onartuzumab | 3.7 (0.4) | 3.8 (0.4) | 4.5 (0.9) | 5.8 (0.7) | 5.3 (0.6) | -- | -- |
*Each value represents the mean ratio with the standard deviation below in parenthesis; n= 5.